Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally

Stock Track

07/02

SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.

The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.

Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1123977572"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123977572\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123977572?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 10:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123977572","market":"us","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally","media":"Stock Track","content":"<p>SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.</p><p>The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.</p><p>Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 7.26% Intraday on Strategic AI Investment, Drug Approvals and Sector Rally\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-07-02 10:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.</p><p>The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.</p><p>Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中國生物製藥","start_time":0,"source_url":"","article_id":"1123977572","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123977572","pubTimestamp":1782958283,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.The surge appears driven by multiple positive developments...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"个股追踪|SBP集团盘中大涨7.26%，因战略AI投资、药物获批和板块反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock price soared 7.26% during intraday trading on Thursday, reflecting strong investor interest in the pharmaceutical company.The surge appears driven by multiple positive developments including the company's strategic investment in embodied intelligence firm Zhipingfang through a nearly RMB 5 billion financing round, which signals SBP GROUP's exploration of growth beyond its core pharmaceutical business. Additionally, the company recently announced a HK$2 billion share buyback plan and obtained marketing approval for Peceleganan Spray for wound infections.Further catalysts include the acceptance of its new drug application for tecotabart vedotin (LM-302) for gastric cancer treatment and the presentation of multiple clinical datasets at ASCO, including landmark lung cancer combination therapy results. The broader pharmaceutical sector also provided tailwinds with several major pharma companies posting significant gains during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}